Tocilizumab: Abnormal bone cells in FD/MAS have been shown to secrete interleukin-6 (IL-6), prompting the investigation of tocilizumab, a selective IL-6 inhibitor, as a therapeutic agent in FD/MAS [53]. The gene discussed is IL6; the disease is Fabry disease.